Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)
- 2 January 2019
- journal article
- review article
- Published by Elsevier BV in Pathology
- Vol. 51 (2), 227-232
- https://doi.org/10.1016/j.pathol.2018.10.016
Abstract
No abstract availableKeywords
Funding Information
- Genzyme
- Kowa Company
- Pfizer
- Roche
- Merck Sharp and Dohme
- Novartis
- Sanofi
This publication has 53 references indexed in Scilit:
- Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patientsJournal of Clinical Lipidology, 2011
- Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in EuropeCurrent Opinion in Lipidology, 2010
- Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary eventsNature Reviews Cardiology, 2009
- Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General PopulationCirculation, 2008
- Long-term reduction of C-reactive protein concentration by regular LDL apheresisAtherosclerosis, 2004
- Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemiaThe American Journal of Cardiology, 1998
- An Effective LDL Removal Filter for the Treatment of HyperlipidemiaArtificial Organs, 1995
- Immunosorbent for Selective Removal of Lipoprotein (a) from Human Plasma: In Vitro StudyArtificial Organs, 1991
- Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1984
- PLASMA EXCHANGE IN THE MANAGEMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLÆMIAThe Lancet, 1975